EDEM2
ER degradation-enhancing alpha-mannosidase-like protein 2
Protein Summary
Involved in the endoplasmic reticulum-associated degradation (ERAD) pathway that targets misfolded glycoproteins for degradation in an N-glycan-dependent manner (PubMed:15537790, PubMed:25092655). May initiate ERAD by promoting the first mannose trimming step of ERAD substrates, from Man9GlcNAc2 to Man8GlcNAc2 (PubMed:25092655). Seems to recognize and bind to exposed hydrophobic regions in target proteins (By similarity). In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins (Mast et al., 2005 [PubMed 15537790]).[supplied by OMIM, Mar 2008]
- ENST00000374491
- ENSP00000363615
- ENSG00000088298
- ENST00000374492
- ENSP00000363616
- C20orf31
- C20orf49
- C20orf31
- C20orf49
- bA4204.1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 0.87 | ||
histone modification site profile | 0.83 | ||
pathway | 0.8 | ||
transcription factor binding site profile | 0.67 | ||
cellular component | 0.61 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.45 (req: < 5)
Gene RIFs: 8 (req: <= 3)
Antibodies: 121 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.45 (req: >= 5)
Gene RIFs: 8 (req: > 3)
Antibodies: 121 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0